| Issue Date | Title | Author(s) |
| 2-Nov-2023 | Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF) | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 2024 | Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yin, Hewen; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 2017 | Evaluation of the new Chinese Disseminated Intravascular Coagulation Scoring System in critically ill patients: A multicenter prospective study | Wu, Yingying; Luo, Lili; Niu, Ting; Han, Yue; Feng, Ying; Ding, Qiulan; Huang, Ruibin; Zhang, Xiaohui; Feng, Jianming; Hou, Ming; Peng, Jun; Li, Yan; Zhou, Yuhong; Su, Lei; Yang, Linhua; Zhou, Zeping; Xue, Feng; Gu, Jian; Zhu, Tienan; Wang, Xiaomin; Deng, Jun; Mei, Heng; Hu, Yu |
| 2019 | A multicenter, prospective evaluation of the Chinese Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation | Luo, Lili; Wu, Yingying; Niu, Ting; Han, Yue; Feng, Ying; Ding, Qiulan; Huang, Ruibin; Zhang, Xiaohui; Feng, Jianming; Hou, Ming; Peng, Jun; Li, Yan; Zhou, Yuhong; Su, Lei; Yang, Linhua; Zhou, Zeping; Xue, Feng; Gu, Jian; Zhu, Tienan; Wang, Xiaomin; Deng, Jun; Mei, Heng; Hu, Yu |
| 1-Jun-2023 | A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF). | Zhang, Yi; Zhou, Hu; Zhuang, Junling; He, Aili; Li, Yarong; Yang, Linhua; Du, Xin; Gao, Sujun; He, Guangsheng; Hong, Mei; Jiang, Qian; Jiang, Zhongxing; Sun, Kai; Yue, Lingling; Zheng, Cuiping; Zhou, Zeping; Xiao, Zhi-Jian; Jin, Jie |
| Jul-2023 | Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China | Zhou, Hu; Zhou, Jianfeng; Wu, Depei; Ma, Liping; Du, Xin; Niu, Ting; Yang, Renchi; Liu, Jing; Zhang, Feng; Shi, Qingzhi; Wang, Xiuli; Jing, Hongmei; Li, Junmin; Wang, Xin; Cui, Zhongguang; Zhou, Zeping; Hou, Ming; Shao, Zonghong; Jin, Jie; Li, Wenqian; Ren, Hanyun; Hu, Jianda; Shen, Jianliang; Liu, Li; Zeng, Yun; Zhou, Jin; Liu, Xin; Shen, Yunfeng; Ding, Kai; Taira, Tadaaki; Cai, Huacong; Zhao, Yongqiang |
| Jul-2023 | Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China | Zhou, Hu; Zhou, Jianfeng; Wu, Depei; Ma, Liping; Du, Xin; Niu, Ting; Yang, Renchi; Liu, Jing; Zhang, Feng; Shi, Qingzhi; Wang, Xiuli; Jing, Hongmei; Li, Junmin; Wang, Xin; Cui, Zhongguang; Zhou, Zeping; Hou, Ming; Shao, Zonghong; Jin, Jie; Li, Wenqian; Ren, Hanyun; Hu, Jianda; Shen, Jianliang; Liu, Li; Zeng, Yun; Zhou, Jin; Liu, Xin; Shen, Yunfeng; Ding, Kai; Taira, Tadaaki; Cai, Huacong; Zhao, Yongqiang |
| Oct-2022 | Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yu, Wenjuan; Jin, Jie |
